The United Kingdom has now adopted the first subscription payment model of the world for the two antibiotics, and the National Health Service (NHS) is going to be paying Shionogi and Pfizer up to 10 million pounds a yare for a decade for them regardless of how many doses the antibiotics have been administered to the patients.
The payment scheme has been aiming to provide the financial incentives for the companies for the purpose of developing the new antimicrobials, and the new drugs known as Fetroja and Zavicefta is also going to be given to the patients with serious drug-resistant infections which is otherwise going to have limited treatment options.
According to the National Institute of Health and Care Excellent (NICE), whose assessment of the value of the drugs for the money underpinned the decision, and according to UK review programme between 2014 and 2016. The company has also predicted that, there can possibly be 300 million premature deaths by the year 2050 and 100 trillion dollars that are lost to the global economy because of the antimicrobial resistance and has also highlighted the need for encouraging the supply of the new drugs.
This approach has been undercutting the financial incentives for the purpose of developing the new antibiotics and they also administered to a small number of the patients for very short period of time and hence the revenues for the companies have been limited and is also leading the healthcare providers for exploring the new models for incentivising the development.